I read the transcript, of that interview, and I came away with the same feeling. It seemed like the interviewer gave him an excellent opportunity to discuss Leronlimab controlling the tumor microenvironment, and raising PDL-1 expression (turning cold tumor cells hot, for more complete treatment with a PD-1 and PDL-1 checkpoint inhibitor). Unfortunately, he decided to not include it in his response. Weird!
CMedEd | Updates | 2025-10-08 CMedEd Interviews Dr. Naoto Ueno on the Latest News in Breast Cancer Treatment https://share.google/sqaRvvoOcgxkCRAvj